Sign In
Buy BIOA
$16.04
-0.500 (-3.02%)
At Close: Jun 03, 2026
Crude Oil Gains 2%; BioAge Labs Shares Plunge
01:23pm, Monday, 09'th Dec 2024
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday.
BOSTON, MA / ACCESSWIRE / December 9, 2024 / Block & Leviton is investigating BioAge Labs, Inc. (Nasdaq:BIOA) for potential securities law violations. Investors who have lost money in their BioAge Lab
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:20am, Monday, 09'th Dec 2024
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
07:41am, Monday, 09'th Dec 2024
On Friday, BioAge Labs Inc. BIOA announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.
BioAge discontinues mid-stage trial of obesity drug
04:47pm, Friday, 06'th Dec 2024
BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's tirzepatide for the treatment of obesity.
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
04:30pm, Thursday, 05'th Dec 2024
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates f
BioAge Labs to Present at Upcoming Investor Conferences
04:30pm, Thursday, 21'st Nov 2024
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates f
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
04:30pm, Thursday, 07'th Nov 2024
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents su
Prediction: These 2 Stocks Could Soar in 2025
09:45am, Thursday, 17'th Oct 2024
The key word here is "could."
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
09:30am, Sunday, 13'th Oct 2024
The future of the weight loss market might not revolve around GLP-1 drugs.
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
02:31pm, Saturday, 12'th Oct 2024
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
08:00am, Monday, 07'th Oct 2024
One of these businesses is a risky play, but the other is very likely to succeed.
An Airline, Biotechs, and More See Huge Insider Buying
09:45am, Sunday, 06'th Oct 2024
24/7 Wall St. Insights Public offerings of stock and activist investor activity have prompted some huge insider buying.
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
07:15am, Saturday, 05'th Oct 2024
There's a chance that its lead candidate could become one of the top drugs ever.
